Project Grant R21AG101017
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $520K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
- This federal Project Grant award of $2,833,089 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes. The award will support research to investigate the roles of the TREM2 and TYROBP genes and their impact on network hyperexcitability, which may contribute to cognitive decline in Alzheimer's disease and related dementias. Key objectives include determining whether TYROBP hypofunction exacerbates network...
- The National Institute of Neurological Disorders and Stroke awarded J. David Gladstone Institutes $122,850 on February 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate microglial control of thalamocortical circuits in Alzheimer's disease. The research combines electrophysiology, transcriptomics, and behavioral analysis to determine how the TREM2R47H genetic variant—which increases Alzheimer's disease risk...
- The National Institute on Aging awarded the University of California, Los Angeles $126,063 on August 5, 2026, under the Aging Research program (CFDA 93.866) to determine the atomic structures of amyloid-beta and tau oligomers and to characterize the molecular interaction between amyloid-beta and the TREM2 receptor on microglia. The award is classified as a Project Grant, specifically a K99/R00 award. The research develops a novel oligomer structure determination pipeline incorporating native...
- The National Institute on Aging awarded Temple University $132,448 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate NMDAR/TRPM4 signaling and mitochondrial dysfunction in Alzheimer's disease. The project tests the functional coupling of N-methyl-D-aspartate receptors (NMDARs) and TRPM4 channels as a central mechanism of neurotoxicity in Alzheimer's disease and related dementias. Research employs induced pluripotent stem cell organoids carrying AD-causing...
- The National Institute on Aging awarded The Feinstein Institutes For Medical Research $2,557,950 on May 15, 2026, under the Aging Research program (CFDA 93.866) to investigate extracellular cold-inducible RNA-binding protein (ECIRP) as a driver of neurotoxic astrocytes in Alzheimer's disease pathogenesis and to evaluate ECIRP-targeting as a potential therapeutic approach. The research will examine the molecular mechanism by which ECIRP induces neurotoxic astrocytes and their contribution to...
- The National Institute on Aging awarded the University of California, San Diego $408,012 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop methods for improving central nervous system pharmacokinetics of targeted protein degraders through specialized assay workflows and prodrug chemistries. The research will establish dual-functional molecules that hijack endogenous molecular transport pathways to cross the blood-brain barrier, with early-stage application to...
- The National Institute on Aging awarded The Leland Stanford Junior University $149,190 on July 29, 2026, under the Aging Research program (CFDA 93.866) to develop and assess highly specific positron emission tomography (PET) tracers for imaging innate immune activation in Alzheimer's disease. The project focuses on creating GPR84-specific PET radiotracers, [11C]GLPG-38 and [18F]MGX-110S, to address limitations in existing neuroinflammation biomarkers. Current PET biomarkers of...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of semaphorin 3A in microglial activation and Alzheimer's disease pathology. The research will determine the functional role and mechanistic basis for semaphorin 3A–mediated regulation of microglial activation in Alzheimer's disease. Building on preliminary findings using human induced pluripotent...
- The National Institute on Aging awarded the Scripps Research Institute $2.613 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate a druggable mito-nuclear feedback mechanism that preserves mitochondrial and synaptic function in aging and Alzheimer's disease. The research focuses on elucidating how age and pathological tau destabilize a brain-specific mito-nuclear feedback loop that controls mitochondrial gene expression in response to acetyl-CoA...
- The National Institute on Aging awarded the University of Texas Medical Branch at Galveston $1.788 million on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the interplay between microglia and tau oligomer polymorphs in cognitive resilience among individuals with Alzheimer's disease neuropathology who remain cognitively intact. The project tests the hypothesis that brain-derived tau oligomers isolated from cognitively resilient individuals exhibit reduced toxicity...